The Anticariogenic Effect of Miswak (Silvadora Persica) and Grape Seed Extract

October 21, 2019 updated by: Hala Ahmed Abdel Moneim, Al-Azhar University
Prevention of dental caries has taken a great importance in the last decade. The use of herbal and natural products became mandatory to avoid the side effects of commercially available medications. Aim of the study; the aim was to investigate the anti-cariogenic effect of miswak and grape seed extract (GSE).

Study Overview

Detailed Description

Patients used Miswak sticks, grape seed extract mouth wash and fluoride mouthwash twice daily for three month. Saliva samples were collected at base line and after one month and three month. Assessment of bacterial count and saliva buffering capacity were performed at base line and after one and three month.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nasr City
      • Cairo, Nasr City, Egypt
        • Al Azhar University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with high caries risk
  • Males or females
  • Medically free patients
  • Patients approving to participate in the study

Exclusion Criteria:

  • Patients who were on antibiotic therapy or corticosteroid therapy for 30 days before the examination
  • Patients had history of professional cleaning in the last 15 days
  • Patients with exposed pulp
  • Evidence of parafunctional habits
  • Patients with developmental dental anomalies
  • Patients undergoing or will start orthodontic treatment
  • Patients with removable prosthesis
  • Periapical Abscess or Fistula

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Miswak
Miswak sticks used twice daily, every 12 hours, for three months.
sticks
Other Names:
  • silvadora persica
Experimental: Grape Seed Extract
Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
Mouthwash
Other Names:
  • 95% proanthocyanidins
Active Comparator: Fluoride Mouthwash
0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
mouthwash
Other Names:
  • 0.05% sodium fluoride

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
quantitative measure of the change in salivary streptococcus mutans Count from baseline to one month and three months.
Time Frame: Baseline, one month, three months.
the patients used the treatments twice daily for three months. unstimulated saliva samples were collected from the patients at baseline,after one month and after three months. Every time samples were incubated with Mitiis Salivaris with Bacitricin and 20% sucrose for streptococcus mutans count.
Baseline, one month, three months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
quantitative measure of the change in saliva buffering capacity from baseline to one month and three months.
Time Frame: baseline, one month , three months
the patients used the treatments twice daily for three months. unstimulated saliva samples were collected from the patients at baseline, after one month and after three months. each time, saliva buffering capacity was measured using Hand Held pH meter and 0.1 mol/l hydrochloric acid that was titrated to the tested saliva.
baseline, one month , three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Maha Niazy, professor, Al-Azhar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2019

Primary Completion (Actual)

August 31, 2019

Study Completion (Actual)

October 1, 2019

Study Registration Dates

First Submitted

October 19, 2019

First Submitted That Met QC Criteria

October 21, 2019

First Posted (Actual)

October 23, 2019

Study Record Updates

Last Update Posted (Actual)

October 23, 2019

Last Update Submitted That Met QC Criteria

October 21, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dental Caries

Clinical Trials on Miswak

Subscribe